Pfizer beats estimates but maintains 2016 profit forecast | Fin24
  • Covid-19 Money Hub

    The hub will help answer your business and money questions during the coronavirus crisis.

  • Cigarettes

    The tobacco ban is a 'deal with the devil' that undermines transformation, say lobby groups.

  • Easing the Lockdown

    Liquor makers want bars to become drink-collection points when the alcohol ban lifts.


Pfizer beats estimates but maintains 2016 profit forecast

Aug 02 2016 16:45

London - Pfizer reported better-than-expected quarterly revenue and profit, driven by sales of newer drugs and the acquisition of hospital products company Hospira.

The largest US drugmaker's revenue rose about 11% to $13.15bn in the second quarter, edging past the average analyst estimate of $13.01bn.

Sales of generic medicines rose 15.7% in the quarter to $6.04bn, while sales of its array of patent-protected drugs jumped 7.2% to about $7.11bn.

Pfizer last year completed its $16bn purchase of Hospira, which makes a wide array of drugs and devices used in hospitals, especially sterile injectable products. Hospira products posted sales of about $1.14bn in the quarter.

The company's recently launched breast cancer treatment, Ibrance, generated sales of $514m, up from $140m in the year-ago quarter and eclipsing the average Wall Street expectation of $496m, compiled by Evercore ISI.

Pfizer, which in April terminated its $160bn tax inversion deal to acquire Irish drugmaker Allergan, said it earned 64 cents per share, excluding special items, beating the average analyst estimate by 2 cents.

Fin24's top stories trending on Twitter:

pfizer  |  health  |  earnings reports


Company Snapshot

Voting Booth

How has Covid-19 impacted your financial position?

Previous results · Suggest a vote